Valravillon

Researchers are evaluating the efficacy of the drug RO7837195 compared to a placebo in adults with moderately to severely active ulcerative colitis UC who have not responded well to conventional or advanced treatments. This Phase IIb study aims to assess the safety, pharmacokinetics, and clinical effects of RO7837195 in this patient group. The study is sponsored by Genentech, Inc. and focuses on treatment outcomes including clinical remission at Week 12. Participants undergo a screening period lasting up to 5 weeks, followed by a 12-week induction phase where some receive RO7837195 and others receive a placebo. After this, all participants enter a 40-week active treatment extension phase receiving RO7837195 regardless of their initial response. This design allows comparison during induction and continued treatment for all in the extension phase. Safety follow-up occurs after the last dose of study treatment. Throughout the trial, participants will be monitored for clinical remission, response, and endoscopic improvements at Week 12, as well as adverse events and drug concentration levels up to Week 65. The study includes regular evaluations such as clinical assessments and laboratory tests to track treatment effects and safety. Total participation can last up to approximately 57 weeks, covering screening, treatment, and follow-up periods.

Researchers are evaluating the ability of a new blood test called Guardant Reveal, developed by Guardant Health, to detect cancer recurrence in people treated for early-stage solid tumors. This observational study aims to link the blood test results with clinical outcomes to show its potential value in monitoring cancer recurrence while considering healthcare costs. The study includes multiple types of cancers such as bladder, lung, breast, melanoma, esophageal, gastric, pancreatic, head and neck, ovarian, endometrial, renal, and rectal cancers. Participants are grouped into different cohorts based on their specific cancer type and stage, including muscle invasive carcinoma, non-small cell lung cancer, various types of breast cancer, melanoma, esophageal, gastric, pancreatic adenocarcinoma, head and neck squamous cell carcinoma, ovarian or fallopian tube carcinoma, endometrial carcinoma, renal cell carcinoma, and rectal adenocarcinoma. The study involves regular blood sample collection using the Guardant Reveal assay at enrollment and during routine medical visits, with follow-up lasting up to 5 years for ongoing monitoring of minimal residual disease and recurrence detection. During the study, participants will provide blood samples at scheduled visits aligned with their regular cancer care follow-up. Researchers will assess outcomes including the time without distant cancer recurrence over 3 years, along with test sensitivity, positive predictive value, and lead time for recurrence detection. Clinical data will be collected and shared anonymously with investigators, and participants will be monitored according to standard care practices throughout the study duration, which may extend up to 5 years or until the study ends in 2029.

Researchers are studying patients with metastatic colorectal cancer to identify clinical and biological factors that predict how well fruquintinib works in real-world settings. The study aims to confirm survival and safety results seen in previous trials and to better understand treatment outcomes, especially in older patients aged 70 and above, who have been underrepresented in earlier research. This cohort is designed to optimize treatment pathways by pinpointing patients who may benefit most from fruquintinib. Participants will receive fruquintinib, an oral drug that targets specific blood vessel growth receptors, given as 5 mg daily for 21 days followed by a 7-day break. This cycle repeats until the cancer progresses, unacceptable side effects occur, the patient dies, or the patient chooses to stop treatment. The study includes patients treated under compassionate use or after marketing authorization in France, integrating routine clinical practice data. During the study, participants will be monitored for overall survival up to one year after starting treatment, which is the main outcome measured. Additional monitoring includes progression-free survival within the same timeframe. The study involves collecting biological samples like circulating tumor DNA and tumor tissue blocks. Safety, survival, and treatment response data will be gathered to support understanding of fruquintinibs effects in everyday clinical use. The study is expected to continue until the end of 2031.